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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Prevention, 
the National Institutes of Health, and other government agen-
cies, brings together the most up-to-date statistics on heart 
disease, stroke, other vascular diseases, and their risk factors 
and presents them in its Heart Disease and Stroke Statisti-
cal Update . The Statistical Update is a critical resource for 
researchers, clinicians, healthcare policy makers, media pro-
fessionals, the lay public, and many others who seek the best 
available national data on heart disease, stroke, and other car-
diovascular disease–related morbidity and mortality and the 
risks, quality of care, use of medical procedures and opera-
tions, and costs associated with the management of these dis-
eases in a single document . Indeed, since 1999, the Statistical 
Update has been cited >10 500 times in the literature, based 
on citations of all annual versions . In 2012 alone, the various 
Statistical Updates were cited ≈3500 times (data from Google 
Scholar) . In recent years, the Statistical Update has undergone 
some major changes with the addition of new chapters and 
major updates across multiple areas, as well as increasing the 
number of ways to access and use the information assembled .
For this year’s edition, the Statistics Committee, which pro-
duces the document for the AHA, updated all of the current 
chapters with the most recent nationally representative data and 
inclusion of relevant articles from the literature over the past year . 
This year’s edition includes a new chapter on peripheral artery 
disease, as well as new data on the monitoring and benefits of car-
diovascular health in the population, with additional new focus 
on evidence-based approaches to changing behaviors, imple-
mentation strategies, and implications of the AHA’s 2020 Impact 
Goals . Below are a few highlights from this year’s Update .
The 2014 Update Expands Data Coverage of the 
Epidemic of Poor Cardiovascular Health Behaviors 
and Their Antecedents and Consequences
●● Adjusted estimated population attributable fractions for car-
diovascular disease (CVD) mortality were as follows1: 40 .6% 
(95% confidence interval [CI], 24 .5%–54 .6%) for high 
blood pressure; 13 .7% (95% CI, 4 .8%–22 .3%) for smoking; 
13 .2% (95% CI, 3 .5%–29 .2%) for poor diet; 11 .9% (95% 
CI, 1 .3%–22 .3%) for insufficient physical activity; and 8 .8% 
(95% CI, 2 .1%–15 .4%) for abnormal blood glucose levels .
●● Although significant progress has been made over the 
past 4 decades, in 2012, among Americans ≥18 years of 
age, 20 .5% of men and 15 .9% of women continued to be 
cigarette smokers . In 2011, 18 .1% of students in grades 
9 through 12 reported current cigarette use .
●● The percentage of the nonsmoking population with expo-
sure to secondhand smoke (as measured by serum coti-
nine levels ≥0 .05 ng/mL) declined from 52 .5% in 1999 to 
2000 to 40 .1% in 2007 to 2008 . More than half of children 
3 to 11 years of age (53 .6%) and almost half of those 12 to 
19 years of age (46 .5%) had detectable levels, compared 
with just over a third of adults 20 years of age and older 
(36 .7%) .
●● The proportion of youth (≤18 years of age) who report 
engaging in no regular physical activity is high, and the 
proportion increases with age . 
●● In 2011, among adolescents in grades 9 through 12, 17 .7% of 
girls and 10 .0% of boys reported that they had not engaged 
in ≥60 minutes of moderate to vigorous physical activity 
(defined as any activity that increased heart rate or breathing 
rate) at least once in the previous 7 days, despite recommen-
dations that children engage in such activity 7 days per week .
●● In 2012, 29 .9% of adults reported engaging in no aerobic 
leisure-time physical activity .
●● In 2009 to 2010, <1% of Americans met at least 4 of 5 healthy 
dietary goals . Among adults aged ≥20 years, only 12 .3% 
met recommended goals for fruits and vegetables; 18 .3% 
met goals for fish; 0 .6% met goals for sodium; 51 .9% met 
goals for sugar-sweetened beverages; and 7 .3% met goals for 
whole grains . These proportions were even lower in children, 
with only 29 .4% of adolescents aged 12 to 19 years meeting 
goals for low sugar-sweetened beverage intake .
●● The estimated prevalence of overweight and obesity in 
US adults (≥20 years of age) is 154 .7 million, which rep-
resented 68 .2% of this group in 2010 . Nearly 35% of US 
adults are obese (body mass index ≥30 kg/m2) . Men and 
women of all race/ethnic groups in the population are 
affected by the epidemic of overweight and obesity .
●● Among children 2 to 19 years of age, 31 .8% are overweight 
and obese (which represents 23 .9 million children) and 
16 .9% are obese (12 .7 million children) . Mexican Ameri-
can boys and girls and African American girls are dispro-
portionately affected . From 1971-1974 to 2007-2010, the 
prevalence of obesity in children 6 to 11 years of age has 
increased from 4 .0% to 18 .8% .
●● Obesity (body mass index ≥30 kg/m2) is associated with 
marked excess mortality in the US population . Even more 
notable is the excess morbidity associated with overweight 
and obesity in terms of risk factor development and inci-
dence of diabetes mellitus, CVD end points (including coro-
nary heart disease, stroke, and heart failure), and numerous 
other health conditions, including asthma, cancer, end-stage 
renal disease, degenerative joint disease, and many others .
Prevalence and Control of Cardiovascular  
Health Factors and Risks Remain an Issue  
for Many Americans
●● An estimated 31 .9 million adults ≥20 years of age have 
total serum cholesterol levels ≥240 mg/dL, with a preva-
lence of 13 .8% .
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●● Based on 2007 to 2010 data, 33 .0% of US adults ≥20 years 
of age have hypertension . This represents ≈78 million US 
adults with hypertension . The prevalence of hypertension is 
similar for men and women . African American adults have 
among the highest prevalence of hypertension (44%) in the 
world .
●● Among hypertensive Americans, ≈82% are aware of their 
condition and 75% are using antihypertensive medication, 
but only 53% of those with documented hypertension have 
their condition controlled to target levels .
●● In 2010, an estimated 19 .7 million Americans had diag-
nosed diabetes mellitus, representing 8 .3% of the adult 
population . An additional 8 .2 million had undiagnosed dia-
betes mellitus, and 38 .2% had prediabetes, with abnormal 
fasting glucose levels . African Americans, Mexican Ameri-
cans, Hispanic/Latino individuals, and other ethnic minori-
ties bear a strikingly disproportionate burden of diabetes 
mellitus in the United States .
●● The prevalence of diabetes mellitus is increasing dramati-
cally over time, in parallel with the increases in prevalence 
of overweight and obesity .
Rates of Death Attributable to CVD Have Declined, 
but the Burden of Disease Remains High
●● The 2010 overall rate of death attributable to CVD was 
235 .5 per 100 000 . The rates were 278 .4 per 100 000 for 
white males, 369 .2 per 100 000 for black males, 192 .2 per 
100 000 for white females, and 260 .5 per 100 000 for black 
females .
●● From 2000 to 2010, death rates attributable to CVD 
declined 31 .0% . In the same 10-year period, the actual 
number of CVD deaths per year declined by 16 .7% . Yet in 
2010, CVD (I00–I99; Q20–Q28) still accounted for 31 .9% 
(787 650) of all 2 468 435 deaths, or ≈1 of every 3 deaths in 
the United States .
●● On the basis of 2010 death rate data, >2150 Americans die 
of CVD each day, an average of 1 death every 40 seconds . 
About 150 000 Americans who died of CVD in 2010 were 
<65 years of age . In 2010, 34% of deaths attributable to 
CVD occurred before the age of 75 years, which is before 
the current average life expectancy of 78 .7 years .
●● Coronary heart disease alone caused ≈1 of every 6 deaths 
in the United States in 2010 . In 2010, 379 559 Americans 
died of CHD . Each year, an estimated ≈620 000 Americans 
have a new coronary attack (defined as first hospitalized 
myocardial infarction or coronary heart disease death) and 
≈295 000 have a recurrent attack . It is estimated that an 
additional 150 000 silent first myocardial infarctions occur 
each year . Approximately every 34 seconds, 1 American 
has a coronary event, and approximately every 1 minute 23 
seconds, an American will die of one .
●● From 2000 to 2010, the relative rate of stroke death fell by 
35 .8% and the actual number of stroke deaths declined by 
22 .8% . Yet each year, ≈795 000 people continue to experi-
ence a new or recurrent stroke (ischemic or hemorrhagic) . 
Approximately 610 000 of these are first events and 185 000 
are recurrent stroke events . In 2010, stroke caused ≈1 of 
every 19 deaths in the United States . On average, every 40 
seconds, someone in the United States has a stroke, and 
someone dies of one approximately every 4 minutes .
●● The decline in stroke mortality over the past decades, a 
major improvement in population health observed for 
both sexes and all race and age groups, has resulted from 
reduced stroke incidence and lower case fatality rates . The 
significant improvements in stroke outcomes are concur-
rent with cardiovascular risk factor control interventions . 
The hypertension control efforts initiated in the 1970s 
appear to have had the most substantial influence on the 
accelerated decline in stroke mortality, with lower blood 
pressure distributions in the population . Control of diabe-
tes mellitus and high cholesterol and smoking cessation 
programs, particularly in combination with hypertension 
treatment, also appear to have contributed to the decline 
in stroke mortality .2
●● In 2010, 1 in 9 death certificates (279 098 deaths) in the 
United States mentioned heart failure . Heart failure was the 
underlying cause in 57 757 of those deaths in 2010 . The 
number of any-mention deaths attributable to heart failure 
was approximately as high in 1995 (287 000) as it was in 
2010 (279 000) . Additionally, hospital discharges for heart 
failure remained stable from 2000 to 2010, with first-listed 
discharges of 1 008 000 and 1 023 000, respectively .
The 2014 Update Provides Critical Data About 
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs
In light of the current national focus on healthcare utilization, 
costs, and quality, it is critical to monitor and understand the 
magnitude of healthcare delivery and costs, as well as the 
quality of healthcare delivery, related to CVD risk factors and 
conditions . The Statistical Update provides these critical data 
in several sections .
Quality-of-Care Metrics for CVDs
Quality data are available from the AHA’s Get With The Guide-
lines programs for coronary heart disease, heart failure, and 
resuscitation and from the American Stroke Association/AHA’s 
Get With The Guidelines program for acute stroke . Similar 
data from the Veterans Healthcare Administration, national 
Medicare and Medicaid data, and Acute Coronary Treatment 
and Intervention Outcomes Network (ACTION)–Get With The 
Guidelines Registry data are also reviewed . These data show 
impressive adherence to guideline recommendations for many, 
but not all, metrics of quality of care for these hospitalized 
patients . Data are also reviewed on screening for CVD risk fac-
tor levels and control .
Cardiovascular Procedure Use and Costs
●● The total number of inpatient cardiovascular operations 
and procedures increased 28%, from 5 939 000 in 2000 to 
7 588 000 in 2010 (National Heart, Lung, and Blood Insti-
tute computation based on National Center for Health Sta-
tistics annual data) .
●● The total direct and indirect cost of CVD and stroke in 
the United States for 2010 is estimated to be $315 .4 bil-
lion . This figure includes health expenditures (direct costs, 
which include the cost of physicians and other profession-
als, hospital services, prescribed medications, home health 
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care, and other medical durables) and lost productivity that 
results from premature mortality (indirect costs) .
●● By comparison, in 2008, the estimated cost of all cancer 
and benign neoplasms was $201 .5 billion ($77 .4 billion in 
direct costs, and $124 billion in mortality indirect costs) . 
CVD costs more than any other diagnostic group .
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current infor-
mation available in the Statistics Update .
This annual Statistical Update is the product of an entire 
year’s worth of effort by dedicated professionals, volunteer 
physicians and scientists, and outstanding AHA staff members, 
without whom publication of this valuable resource would be 
impossible . Their contributions are gratefully acknowledged .
Alan S. Go, MD
Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of National 
Health and Nutrition Examination Survey (NHANES) prevalence 
estimates are for the latest year of the NHANES survey being 
used . Extrapolations for NHANES prevalence estimates are based 
on the census resident population for 2010 because this is the most 
recent year of NHANES data used in the Statistical Update .
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Table 1. Males and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Males White Males Black Males Mexican American Males
Smoking
  Prevalence, 2012* 42.1 M (18.1%) 23.0 M (20.5%) 22.0% 21.6% 16.6%†
PA‡
  Prevalence, 2012* 20.7% 24.6% 26.0% 23.7% 19.3%†
Overweight and obesity
  Prevalence, 2010
   Overweight and obesity, BMI >25.0 
kg/m2§
154.7 M (68.2%) 79.9 M (72.9%) 73.1% 68.7% 81.3%
   Obesity, BMI >30.0 kg/m2§ 78.4 M (34.6%) 36.8 M (33.6%) 33.8% 37.9% 36.0%
Blood cholesterol
  Prevalence, 2010
   Total cholesterol >200 mg/dL§ 98.9 M (43.4%) 45.3 M (41.3%) 40.5% 38.6% 48.1%
   Total cholesterol >240 mg/dL§ 31.9 M (13.8%) 14.0 M (12.7%) 12.3% 10.8% 15.2%
   LDL cholesterol >130 mg/dL§ 71.0 M (31.1%) 35.2 M (31.9%) 30.1% 33.1% 39.9%
   HDL cholesterol <40 mg/dL§ 48.7 M (21.8%) 34.6 M (31.8%) 33.1% 20.3% 34.2%
HBP
  Prevalence, 2010§ 77.9 M (33.0%) 37.2 M (33.6%) 33.4% 42.6% 30.1%
  Mortality, 2010‖ 63 119 28 373 20 819 6670 N/A
DM
  Prevalence, 2010
   Physician-diagnosed DM§ 19.7 M (8.3%) 9.6 M (8.7%) 7.7% 13.5% 11.4%
   Undiagnosed DM§ 8.2 M (3.5%) 5.3 M (4.7%) 4.5% 4.8% 6.6%
   Prediabetes§ 87.3 M (38.2%) 50.7 M (46.0%) 47.7% 35.7% 47.0%
   Incidence, diagnosed DM§ 1.9 M N/A N/A N/A N/A
  Mortality, 2010‖ 69 071 35 490 28 486 5640 N/A
Total CVD
  Prevalence, 2010§ 83.6 M (35.3%) 40.7 M (36.7%) 36.6% 44.4% 33.4%
  Mortality, 2010‖¶ 787 650 387 318 330 330 46 266 N/A
Stroke
  Prevalence, 2010§ 6.8 M (2.8%) 3.0 M (2.6%) 2.4% 4.3% 2.3%
  New and recurrent strokes‖ 795.0 K 370.0 K 325.0 K 45.0 K N/A
  Mortality, 2010‖ 129 476 52 367 43 424 6938 N/A
CHD
  Prevalence, CHD, 2010§ 15.4 M (6.4%) 8.8 M (7.9%) 8.2% 6.8% 6.7%
  Prevalence, MI, 2010§ 7.6 M (2.9%) 5.0 M (4.2%) 4.4% 3.9% 3.6%
  Prevalence, AP, 2010§ 7.8 M (3.2%) 3.7 M (3.3%) 3.3% 2.4% 3.4%
  New and recurrent CHD#** 915.0 K 530.0 K 465.0 K 65.0 K N/A
  New and recurrent MI** 720.0 K 420.0 K N/A N/A N/A
  Incidence, AP (stable angina)‡‡ 565.0 K 370.0 K N/A N/A N/A
  Mortality, 2010, CHD‖ 379 559 207 580 181 386 20 615 N/A
  Mortality, 2010, MI‖ 122 071 67 435 59 181 6445 N/A
HF
  Prevalence, 2010§ 5.1 M (2.1%) 2.7 M (2.5%) 2.5% 4.1% 1.9%
  Incidence, 2010‡‡ 825 000 395 000 350 000 45 000 N/A
  Mortality, 2010‖ 57 757 24 385 21 540 2444 N/A
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or both); CVD, cardiovascular disease; DM, 
diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, millions; MI, myocardial infarction (heart attack); 
N/A, data not available; and PA, physical activity.
*Age ≥18 y (National Health Interview Survey).
†All Hispanic (National Health Interview Survey).
‡Met 2008 full Federal PA guidelines for adults.
§Age ≥20 y.
‖All ages.
¶Total CVD mortality includes deaths from congenital heart disease.
#New and recurrent MI and fatal CHD.
**Age ≥35 y.
‡‡Age ≥45 y.
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Table 2. Females and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Females White Females Black Females Mexican American Females
Smoking
  Prevalence, 2012* 42.1 M (18.1%) 19.1 M (15.9%) 19.2% 14.2% 7.5%†
PA‡
  Prevalence, 2012* 20.7% 17.1% 19.9% 10.8% 12.2%†
Overweight and obesity
  Prevalence, 2010
   Overweight and obesity, BMI >25.0 kg/m2§ 154.7 M (68.2%) 74.8 M (63.7%) 60.2% 79.9% 78.2%
   Obesity, BMI >30.0 kg/m2§ 78.4 M (34.6%) 41.6 M (35.6%) 32.5% 53.9% 44.8%
Blood cholesterol
  Prevalence, 2010
   Total cholesterol >200 mg/dL§ 98.9 M (43.4%) 53.6 M (44.9%) 45.8% 40.7% 44.7%
   Total cholesterol >240 mg/dL§ 31.9 M (13.8%) 17.9 M (14.7%) 15.6% 11.7% 13.5%
   LDL cholesterol >130 mg/dL§ 71.0 M (31.1%) 35.8 M (30.0%) 29.3% 31.2% 30.4%
   HDL cholesterol <40 mg/dL§ 48.7 M (21.8%) 14.1 M (12.3%) 12.4% 10.2% 15.1%
HBP
  Prevalence, 2010§ 77.9 M (33.0%) 40.7 M (32.2%) 30.7% 47.0% 28.8%
  Mortality, 2010|| 63 119 34 746 26 798 6923 N/A
DM
  Prevalence, 2010
   Physician-diagnosed DM§ 19.7 M (8.3%) 10.1 M (7.9%) 6.2% 15.4% 12.0%
   Undiagnosed DM§ 8.2 M (3.5%) 2.9 M (2.3%) 1.8% 2.9% 4.7%
   Prediabetes§ 87.3 M (38.2%) 33.6 M (30.5%) 30.0% 29.0% 31.9%
   Incidence, diagnosed DM§ 1.9 M N/A N/A N/A N/A
  Mortality, 2010|| 69 071 33 581 25 764 6486 N/A
Total CVD
  Prevalence, 2010§ 83.6 M (35.3%) 42.9 M (34.0%) 32.4% 48.9% 30.7%
  Mortality, 2010||¶ 787 650 400 332 342 581 49 977 N/A
Stroke
  Prevalence, 2010§ 6.8 M (2.8%) 3.8 M (3.0%) 2.9% 4.7% 1.4%
  New and recurrent strokes|| 795.0 K 425.0 K 365.0 K 60.0 K N/A
  Mortality, 2010|| 129 476 77 109 65 695 9027 N/A
CHD
  Prevalence, CHD, 2010§ 15.4 M (6.4%) 6.6 M (5.1%) 4.6% 7.1% 5.3%
  Prevalence, MI, 2010§ 7.6 M (2.9%) 2.6 M (1.7%) 1.5% 2.3% 1.7%
  Prevalence, AP, 2010§ 7.8 M (3.2%) 4.1 M (3.2%) 2.8% 5.4% 3.3%
  New and recurrent CHD#** 915.0 K 385.0 K 330.0 K 55.0 K N/A
  New and recurrent MI** 720.0 K 300.0 K N/A N/A N/A
  Incidence, AP (stable angina) ‡‡ 565.0 K 195.0 K N/A N/A N/A
  Mortality, 2010, CHD|| 379 559 171 979 148 891 19 015 N/A
  Mortality, 2010, MI|| 122 071 54 636 47 023 6298 N/A
HF
  Prevalence, 2010§ 5.1 M (2.1%) 2.4 M (1.8%) 1.8% 3.0% 1.1%
  Incidence, 2010‡‡ 825 000 430 000 375 000 55 000 N/A
  Mortality, 2010‖ 57 757 33 372 29 750 3084 N/A
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or both); CVD, cardiovascular disease; DM, 
diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, millions; MI, myocardial infarction (heart attack); 
N/A, data not available; and PA, physical activity.
*Age ≥18 y (National Health Interview Survey).
†All Hispanic (National Health Interview Survey).
‡Met 2008 full Federal PA guidelines for adults.
§Age ≥20 y.
‖All ages.
¶Total CVD mortality includes deaths from congenital heart disease.
#New and recurrent MI and fatal CHD.
**Age ≥35 y.
‡‡Age ≥45 y.
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Table 3. Race/Ethnicity and CVD: At-a-Glance Table
Whites Blacks
Mexican 
Americans
Hispanics/ 
Latinos
Asians: Both 
Sexes
American 
Indian/Alaska 
Native: Both 
SexesDiseases and Risk Factors Both Sexes Males Females Males Females Males Females Males Females
Smoking
  Prevalence, 2012* 42.1 M (18.1%) 22.0% 19.2% 21.6% 14.2% 11.3% 16.6% 7.5% 10.4% 18.8%
PA†
  Prevalence, 2012* 20.7% 20.6% 21.4% 14.9% 15.7% 18.7% 16.8%
Overweight and obesity
  Prevalence, 2010
   Overweight and obesity,  
BMI >25.0 kg/m2‡
154.7 M (68.2%) 73.1% 60.2% 68.7% 79.9% 81.3% 78.2% N/A N/A N/A N/A
   Overweight and obesity,  
BMI >30.0 kg/m2‡
78.4 M (34.6%) 33.8% 32.5% 37.9% 53.9% 36.0% 44.8% N/A N/A N/A N/A
Blood cholesterol
  Prevalence, 2010
   Total cholesterol >200 mg/dL‡ 98.9 M (43.4%) 40.5% 45.8% 38.6% 40.7% 48.1% 44.7% N/A N/A N/A N/A
   Total cholesterol >240 mg/dL‡ 31.9 M (13.8%) 12.3% 15.6% 10.8% 11.7% 15.2% 13.5% N/A N/A N/A N/A
   LDL cholesterol >130 mg/dL‡ 71.0 M (31.1%) 30.1% 29.3% 33.1% 31.2% 39.9% 30.4% N/A N/A N/A N/A
   HDL cholesterol <40 mg/dL‡ 48.7 M (21.8%) 33.1% 12.4% 20.3% 10.2% 34.2% 15.1% N/A N/A N/A N/A
HBP
  Prevalence, 2010‡ 77.9 M (33.0%) 33.4% 30.7% 42.6% 47.0% 30.1% 28.8% 20.9%* 21.27%* 24.8%*
  Mortality, 2010§ 63 119 20 819 26 798 6670 6923 N/A N/A N/A N/A 1578 331
DM
  Prevalence, 2010
   Physician-diagnosed DM‡ 19.7 M (8.3%) 7.7% 6.2% 13.5% 15.4% 11.4% 12.0% N/A N/A N/A N/A
   Undiagnosed DM‡ 8.2 M (3.5%) 4.5% 1.8% 4.8% 2.9% 6.6% 4.7% N/A N/A N/A N/A
   Prediabetes‡ 87.3 M (38.2%) 47.7% 30.0% 35.7% 29.0% 47.0% 31.9% N/A N/A N/A N/A
   Incidence, diagnosed DM‡ 1.9 M N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
  Mortality, 2010§ 69 071 28 486 25 764 5640 6486 N/A N/A N/A N/A 1838 857
Total CVD
  Prevalence, 2010‡ 83.6 M (35.3%) 36.6% 32.4% 44.4% 48.9% 33.4% 30.7% N/A N/A N/A N/A
  Mortality, 2010§‖ 787 650 330 330 342 581 46 266 49 977 N/A N/A N/A N/A 16 829 3667
Stroke
  Prevalence, 2010‡ 6.8 M (2.8%) 2.4% 2.9% 4.3% 4.7% 2.3% 1.4% 2.7%* 1.8%* 4.3%*¶
  New and recurrent strokes§ 795.0 K 325.0 K 365.0 K 45.0 K 60.0 K N/A N/A N/A N/A N/A N/A
  Mortality, 2010§ 129 476 43 424 65 695 6938 9027 N/A N/A N/A N/A 3833 559
CHD
  Prevalence, CHD, 2010‡ 15.4 M (6.4%) 8.2% 4.6% 6.8% 7.1% 6.7% 5.3% N/A N/A N/A N/A
  Prevalence, MI, 2010‡ 7.6 M (2.9%) 4.4% 1.5% 3.9% 2.3% 3.6% 1.7% N/A N/A N/A N/A
  Prevalence, AP, 2010‡ 7.8 M (3.2%) 3.3% 2.8% 2.4% 5.4% 3.4% 3.3% N/A N/A N/A N/A
  New and recurrent CHD#** 915.0 K 465.0 K 330.0 K 65.0 K 55.0 K N/A N/A N/A N/A N/A N/A
  Mortality, CHD, 2010§ 379 559 181 386 148 891 20 615 19 015 N/A N/A N/A N/A 7821 1831
  Mortality, MI, 2010§ 122 071 59 181 47 023 6445 6298 N/A N/A N/A N/A 2530 594
HF
  Prevalence, 2010‡ 5.1 M (2.1%) 2.5% 1.8% 4.1% 3.0% 1.9% 1.1% N/A N/A N/A N/A
  Incidence, 2010‡‡ 825 000 350 000 375 000 45 000 55 000 N/A N/A N/A N/A N/A N/A
  Mortality, 2010§ 57 757 21 540 29 750 2444 3084 N/A N/A N/A N/A 714 225
AP, angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or both); CVD, cardiovascular disease; DM, diabetes 
mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, millions; MI, myocardial infarction (heart attack); N/A, data 
not available; and PA, physical activity;.
*Age ≥18 y (National Health Interview Survey, 2012).
†Met 2008 full Federal PA guidelines for adults.
‡Age ≥20 y.
§All ages.
‖Total CVD mortality includes deaths from congenital heart disease.
¶Figure not considered reliable.
#New and recurrent MI and fatal CHD.
**Age ≥35 y.
‡‡Age ≥45 y.
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Table 4. Children, Youth, and CVD: At-a-Glance Table
NH Whites NH Blacks Mexican Americans
Diseases and Risk Factors Both Sexes Total Males Total Females Males Females Males Females Males Females
Smoking, %
  High school students,  
grades 9–12
   Current cigarette 
smoking, 2011
18.1 19.9 16.1 21.5 18.9 13.7 7.4 19.5* 15.2*
   Current cigar smoking, 
2011
13.1 17.8 8.0 19.0 7.5 15.1 8.5 17.2* 9.1*
PA†
  Prevalence, grades 9–12,  
2011‡
   Met currently 
recommended levels  
of PA, %
49.5 59.9 38.5 62.1 42.6 57.1 31.9 57.1* 33.0*
Overweight and obesity
  Prevalence, 2010
   Children and adolescents, 
ages 2–19 y, overweight 
or obese
23.9 M (31.8%) 12.7 M (33.0%) 11.2 M (30.4%) 30.1% 25.6% 36.9% 41.3% 40.5% 38.2%
   Children and 
adolescents,  
age 2–19 y, obese‡
12.7 M (16.9%) 7.2 M (18.6%) 5.5 M (15.0%) 16.1% 11.7% 24.3% 24.3% 24.0% 18.2%
Blood cholesterol, mg/dL, 2010
  Mean total cholesterol
   Ages 4–11 y 161.9 162.3 161.5 160.9 161.6 165.2 157.9 159.6 160.7
   Ages 12–19 y 158.2 156.1 160.3 156.8 161.1 154.1 160.6 157.8 158.0
  Mean HDL cholesterol
   Ages 4–11 y 53.6 55.1 51.9 53.9 51.4 59.9 55.3 53.5 50.5
   Ages 12–19 y 51.4 49.2 53.6 48.4 53.0 53.9 55.4 47.5 53.3
  Mean LDL cholesterol
   Ages 12–19 y 89.5 88.6 90.5 90.4 90.9 85.8 91.8 90.6 87.1
Congenital cardiovascular defects
  Mortality, 2010§ 3196 1718 1478 1333 1120 311 271 N/A N/A
Overweight indicates a body mass index in the 95th percentile of the Centers for Disease Control and Prevention 2000 growth chart.
CVD indicates cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, millions; N/A, data not available; NH, non-Hispanic; and PA, 
physical activity. 
*All Hispanic subgroups.
†Regular leisure-time PA.
‡Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, McManus T, Chyen D, Whittle L, Lim C, Wechsler H; Centers for Disease Control 
and Prevention. Youth risk behavior surveillance: United States, 2011. MMWR Surveill Summ. 2012;61:1–162.
§All ages.
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